U.S. Markets close in 3 hrs 4 mins
  • S&P 500

    +53.60 (+1.63%)
  • Nasdaq

    +147.03 (+1.35%)
  • Russell 2000

    +34.90 (+2.37%)
  • Crude Oil

    +0.33 (+0.82%)
  • Gold

    +13.50 (+0.72%)
  • Silver

    +0.43 (+1.87%)

    +0.0024 (+0.2099%)
  • 10-Yr Bond

    +0.0040 (+0.61%)
  • Vix

    +0.24 (+0.91%)

    +0.0106 (+0.8301%)

    +127.98 (+1.19%)
  • CMC Crypto 200

    +10.44 (+4.66%)
  • FTSE 100

    +85.26 (+1.46%)
  • Nikkei 225

    +307.00 (+1.32%)

Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta?

If you own shares in Synthetic Biologics Inc (NYSEMKT:SYN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said ‘volatility is far from synonymous with risk’ in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Check out our latest analysis for Synthetic Biologics

What SYN’s beta value tells investors

Looking at the last five years, Synthetic Biologics has a beta of 1.36. The fact that this is well above 1 indicates that its share price movements have shown sensitivity to overall market volatility. Based on this history, investors should be aware that Synthetic Biologics are likely to rise strongly in times of greed, but sell off in times of fear. Many would argue that beta is useful in position sizing, but fundamental metrics such as revenue and earnings are more important overall. You can see Synthetic Biologics’s revenue and earnings in the image below.

AMEX:SYN Income Statement Export October 18th 18
AMEX:SYN Income Statement Export October 18th 18

Does SYN’s size influence the expected beta?

Synthetic Biologics is a rather small company. It has a market capitalisation of US$7m, which means it is probably under the radar of most investors. It takes less money to influence the share price of a very small company. This may explain the excess volatility implied by this beta value.

What this means for you:

Since Synthetic Biologics has a reasonably high beta, it’s worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. In order to fully understand whether SYN is a good investment for you, we also need to consider important company-specific fundamentals such as Synthetic Biologics’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for SYN’s future growth? Take a look at our free research report of analyst consensus for SYN’s outlook.

  2. Past Track Record: Has SYN been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of SYN’s historicals for more clarity.

  3. Other Interesting Stocks: It’s worth checking to see how SYN measures up against other companies on valuation. You could start with this free list of prospective options.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.